New Cardiac Stem Cell Therapy passes Phase I/II Trials – Labiotech.eu (blog)
|
New Cardiac Stem Cell Therapy passes Phase I/II Trials
Labiotech.eu (blog) TiGenix announces positive one-year results for its phase I/II trial of donor-derived cardiac stem cell therapy in acute myocardial infarction (AMI). The Belgian biotech TiGenix is developing allogeneic stem cell therapies. Now the company has … |
